|
|
|
|
|
|
Sponsored by: |
Merck |
Information provided by: | Merck |
ClinicalTrials.gov Identifier: | NCT00328523 |
In patients with primary hypercholesterolemia treated with a statin and with ldl-c above the recommended target goal (esc 2003 recommendations ldl>=1.15 g/l) to compare the efficacy and the safety of ezetrol added to ongoing statin and non drug therapeutic intervention (patient motivation on diet or physical activities or both).
Condition | Intervention | Phase |
Hypercholesterolaemia Hyperlipidaemia |
Drug: MK-0653, ezetimibe Drug: Duration of Treatment: 3 months |
Phase III |
Genetics Home Reference related topics: | hypercholesterolemia |
MedlinePlus related topics: | Cholesterol |
ChemIDplus related topics: | Ezetimibe Cholest-5-en-3-ol (3beta)- |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Uncontrolled, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Ezetimibe Together With Any Statin Cholesterol Enhancement |
Estimated Enrollment: | 1500 |
Study Start Date: | June 2004 |
Ages Eligible for Study: | 18 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | 2006_024 |
First Received: | May 19, 2006 |
Last Updated: | May 19, 2006 |
ClinicalTrials.gov Identifier: | NCT00328523 |
Health Authority: | France: Afssaps - French Health Products Safety Agency |
|
|
|
|